GNTA
HEALTHCAREGenenta Science SpA
$0.69+0.02 (+2.97%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GNTA Today?
No stock-specific AI insight has been generated for GNTA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.59$6.20
$0.69
Fundamentals
Market Cap$16M
P/E Ratio—
EPS$-0.39
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume114K
Avg Volume (10D)—
Shares Outstanding23.6M
GNTA News
18 articles- Genenta signs Definitive Agreements with Sophia High TechGlobeNewswire Inc.·Apr 23, 2026
- Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programsGlobeNewswire Inc.·Mar 27, 2026
- Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi NaldiniYahoo Finance·Mar 24, 2026
- European Equities Traded in the US as American Depositary Receipts Higher TuesdayYahoo Finance·Mar 17, 2026
- Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia UniversityYahoo Finance·Mar 13, 2026
- Genenta Science SPA (GNTA) Shifting from Biotech to Defense BusinessYahoo Finance·Feb 28, 2026
- Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation PlatformYahoo Finance·Feb 27, 2026
- Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial ConsolidatorYahoo Finance·Jan 27, 2026
- European Equities Traded in the US as American Depositary Receipts Gain FridayYahoo Finance·Jan 2, 2026
- Genenta Science Provides Update on CEO OwnershipYahoo Finance·Dec 19, 2025
- Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) TrialYahoo Finance·Nov 24, 2025
- US-China Trade Optimism Lifts US Equity Futures Pre-BellYahoo Finance·Oct 27, 2025
- Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry OptimismYahoo Finance·Oct 27, 2025
- Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary SharesYahoo Finance·Oct 27, 2025
- Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA ProductionYahoo Finance·Oct 24, 2025
- Genenta Science And 2 Other Penny Stocks To ConsiderYahoo Finance·Oct 14, 2025
- Genenta Science Leads The Charge With 2 Other Promising Penny StocksYahoo Finance·Jul 8, 2025
- Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival SignalsYahoo Finance·Jul 1, 2025
All 18 articles loaded
Price Data
Open$0.74
Previous Close$0.67
Day High$0.75
Day Low$0.67
52 Week High$6.20
52 Week Low$0.59
52-Week Range
$0.59$6.20
$0.69
Fundamentals
Market Cap$16M
P/E Ratio—
EPS$-0.39
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume114K
Avg Volume (10D)—
Shares Outstanding23.6M
About Genenta Science SpA
Genenta Science SpA, a clinical-stage biotechnology company, is dedicated to the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company is headquartered in Milan, Italy.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—